China/EU: Lobby slams China’s supposed discrimination against foreign firms
A business lobby in the European Union decried China’s alleged discrimination against foreign firms, specifically in the pharmaceutical market, describing the recent crackdown on non-domestic companies for competition violations as unfair.
Bruno Gensburger, the head of the EU’s Chamber of Commerce in China’s pharmaceutical working group, told reporters Thursday that China has been unfairly targeting companies, stating that, to his knowledge, “no Chinese company has been investigated.”
China denied claims regulators are discriminating their competition probes against foreign firms.
Recent months have shown Chinese regulators to be strengthening their grip on anticompetitive behavior. The largest such instance now is UK-based GlaxoSmithKline, which Chinese regulators have accused of anticompetitive behavior to boost its drug sales.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI